Abstract
Chronic liver and kidney diseases are among the most fearful pathologies affecting an increasing number of people, having severe consequences on life quality. Although much progress has been made in recent years, availability of cost-effective and innovative therapies is still an unmet medical need. One of the major challenges in the therapy of liver and kidney diseases is to selectively deliver drugs to achieve therapeutically relevant concentration in the target organ, in order to decrease the amount of drug needed and to reduce unwanted side effects. In this review we summarize recent advances in selective drug targeting to liver or to kidney including cell-selective therapeutic approaches as well. We pay special attention to plant-derived bioactive molecules which constitute promising tools for the treatment of chronic liver and kidney diseases. We discuss cellular, subcellular and molecular mechanisms underlying the observed pharmacological effects of plant-derived drugs and give an overview of formulations, which can increase therapeutic effectiveness of these biomolecules in the treatment of chronic liver and kidney disorders.
Keywords: liver fibrosis, kidney fibrosis, plant-derived biomolecules, drug delivery.
Current Pharmaceutical Design
Title:Plant-Derived Biomolecules and Drug Delivery Systems in the Treatment of Liver and Kidney Diseases
Volume: 22 Issue: 35
Author(s): Anca Hermenean, Claudia Smeu, Sami Gharbia, Istvan A. Krizbai and Aurel Ardelean
Affiliation:
Keywords: liver fibrosis, kidney fibrosis, plant-derived biomolecules, drug delivery.
Abstract: Chronic liver and kidney diseases are among the most fearful pathologies affecting an increasing number of people, having severe consequences on life quality. Although much progress has been made in recent years, availability of cost-effective and innovative therapies is still an unmet medical need. One of the major challenges in the therapy of liver and kidney diseases is to selectively deliver drugs to achieve therapeutically relevant concentration in the target organ, in order to decrease the amount of drug needed and to reduce unwanted side effects. In this review we summarize recent advances in selective drug targeting to liver or to kidney including cell-selective therapeutic approaches as well. We pay special attention to plant-derived bioactive molecules which constitute promising tools for the treatment of chronic liver and kidney diseases. We discuss cellular, subcellular and molecular mechanisms underlying the observed pharmacological effects of plant-derived drugs and give an overview of formulations, which can increase therapeutic effectiveness of these biomolecules in the treatment of chronic liver and kidney disorders.
Export Options
About this article
Cite this article as:
Hermenean Anca, Smeu Claudia, Gharbia Sami, Krizbai A. Istvan and Ardelean Aurel, Plant-Derived Biomolecules and Drug Delivery Systems in the Treatment of Liver and Kidney Diseases, Current Pharmaceutical Design 2016; 22 (35) . https://dx.doi.org/10.2174/1381612822666160726125157
DOI https://dx.doi.org/10.2174/1381612822666160726125157 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Protein-Energy Malnutrition Alters Thermoregulatory Homeostasis and the Response to Brain Ischemia
Current Neurovascular Research Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Molecular Targets for Modulating Lung Inflammation and Injury
Current Drug Targets Emerging Nanocarriers-based Approaches to Diagnose and Red uce Vascular Inflammation in Atherosclerosis
Current Medicinal Chemistry Unique Coronary Artery Disease Differences in Women as Related to Revascularization
Current Medicinal Chemistry Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Antinociceptive and Anti-Inflammatory Like Effects of <i>Berberis baluchistanica</i>
Current Molecular Pharmacology Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology Manual Thrombectomy During Primary Coronary Intervention in Acute Myocardial Infarction: A Brief Review
Reviews on Recent Clinical Trials Effect of Growth Factors as Therapeutic Drugs on Hepatic Metabolism During the Systemic Inflammatory Response Syndrome
Current Drug Metabolism Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Small Molecule Antagonists of Integrin Receptors
Current Medicinal Chemistry Conserved Domains, Residues, WebLogo and Active Sites of Caspase- Cascades Related to Apoptotic Signaling Pathway
Current Bioinformatics Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Current Medicinal Chemistry Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Nuezhenide Exerts Anti-Inflammatory Activity through the NF-κB Pathway
Current Molecular Pharmacology Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry